Research programme: fully human monoclonal antibodies - Celldex Therapeutics Inc
Alternative Names: CR 010; CR 011; CR 012; CR 031; CR 039; CR 064Latest Information Update: 18 Dec 2023
At a glance
- Originator Amgen; CuraGen Corporation
- Developer Amgen; Celldex Therapeutics Inc; CuraGen Corporation
- Class Drug conjugates; Monoclonal antibodies
- Mechanism of Action Membrane protein inhibitors; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Inflammation
Most Recent Events
- 08 Oct 2020 Seattle Genetics is now called Seagen
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 02 Oct 2009 CuraGen Corporation has been acquired by Celldex Therapeutics Inc